Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients.
About our SPEAR T-cells
Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies.
Our SPEAR T-cell video below provides more information.
Our TCR T-cell therapies are capable of recognizing peptide fragments from both proteins present inside the cell and expressed on the outside of the cell. We can therefore target a large number of proteins.
More targets, inside the cancer cell and out, means more options for targeting these cancers.
Our T-cell therapies are all subjected to a meticulous pre-screening package which aims to minimize any chance that our T-cell therapies might bind to peptides other than the intended target cancer peptide.
Better specificity, we believe, improves the safety profile of our T-cell therapies.
Our T-cell therapies have general applicability to a wide range of cancer types, many of which currently have low patient survival rates.
The foundation of our TCR therapies is the work we did with NY-ESO SPEAR T-cells, which we transitioned to GSK in 2018, showing responses in two solid tumors and treating more than 90 patients in six different indications.
Read below to find out more information about each of our 3 products and the cancer types that they are targeting.
We enhance the body's natural systems by affinity engineering naturally occurring T-cell receptors (TCRs) to recognize and bind to specific cancer peptides.
In addition to our clinical pipeline, we have a large pipeline of identified and validated targets against which we can direct new T-cell therapies.
We believe that our SPEAR T-cell therapies may one day be capable of treating patients who have limited, if any, treatments available.